Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone Propionate and Salmeterol MDPI in Pediatric Asthma
NCT02980133Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2016
- Primary completion
- Apr 2019
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate and salmeterol in asthma (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Change From Baseline in 1-Hour Postdose Percent Predicted Morning Forced Expiratory Volume in 1 Second at 12 weeks and Change From Baseline in Weekly Average of the Percent Predicted Trough Morning FEV1 at 12 weeks. Started Dec 2016; status: completed.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02980133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980133.